Seattle Genetics, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 112

Seattle Genetics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Seattle Genetics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Seattle Genetics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Seattle Genetics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Seattle Genetics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Seattle Genetics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Seattle Genetics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Seattle Genetics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Seattle Genetics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Seattle Genetics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Seattle Genetics, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Seattle Genetics, Inc. Snapshot
Seattle Genetics, Inc. Overview
Key Information
Key Facts
Seattle Genetics, Inc. – Research and Development Overview
Key Therapeutic Areas
Seattle Genetics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Seattle Genetics, Inc. – Pipeline Products Glance
Seattle Genetics, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Seattle Genetics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Seattle Genetics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Seattle Genetics, Inc. – Drug Profiles
Brentuximab Vedotin
Product Description
Mechanism of Action
R&D Progress
Brentuximab Vedotin
Product Description
Mechanism of Action
R&D Progress
Cytarabine + Etoposide + Mitoxantrone + Lintuzumab
Product Description
Mechanism of Action
R&D Progress
Dacetuzumab + Rituxan + Ifosfamide + Carboplatin + Etoposide
Product Description
Mechanism of Action
R&D Progress
Lintuzumab + Cytarabine
Product Description
Mechanism of Action
R&D Progress
Lintuzumab + Cytarabine
Product Description
Mechanism of Action
R&D Progress
SGN-30
Product Description
Mechanism of Action
R&D Progress
ASG-5ME
Product Description
Mechanism of Action
R&D Progress
Brentuximab Vedotin + Adriamycin + Vinblastine + Dacarbazine + Bleomycin
Product Description
Mechanism of Action
R&D Progress
Dacetuzumab + Revlimid + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Lintuzumab
Product Description
Mechanism of Action
R&D Progress
Lintuzumab + Revlimid
Product Description
Mechanism of Action
R&D Progress
SGN-35 + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
SGN-35 + Ketoconazole
Product Description
Mechanism of Action
R&D Progress
SGN-35 + Midazolam
Product Description
Mechanism of Action
R&D Progress
SGN-35 + Rifampin
Product Description
Mechanism of Action
R&D Progress
SGN-40
Product Description
Mechanism of Action
R&D Progress
SGN-40 + Rituxan + Gemzar
Product Description
Mechanism of Action
R&D Progress
SGN-70
Product Description
Mechanism of Action
R&D Progress
SGN-75
Product Description
Mechanism of Action
R&D Progress
ASG-5ME
Product Description
Mechanism of Action
R&D Progress
SGN-19A
Product Description
Mechanism of Action
R&D Progress
Seattle Genetics, Inc. – Pipeline Analysis
Seattle Genetics, Inc. – Pipeline Products by Therapeutic Class
Seattle Genetics, Inc. Pipeline Products By Target
Seattle Genetics, Inc. – Pipeline Products by Route of Administration
Seattle Genetics, Inc. – Pipeline Products by Molecule Type
Seattle Genetics, Inc. – Recent Pipeline Updates
Seattle Genetics, Inc. - Dormant Projects
Seattle Genetics, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
SGN-15 + Taxotere
SGN-40
Seattle Genetics, Inc. – Company Statement
Seattle Genetics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Dec 07, 2010: Seattle Genetics And Millennium Present Positive Phase II Trial Data Of Brentuximab Vedotin In Relapsed Or Refractory ALCL At ASH Annual Meeting
Dec 05, 2010: Seattle Genetics And Millennium Report Positive Data From Pivotal Trial Of Brentuximab Vedotin In Hodgkin Lymphoma
Nov 08, 2010: Seattle Genetics And Millennium To Present Brentuximab Vedotin Clinical Data At American Society Of Hematology Annual Meeting
Nov 03, 2010: Seattle Genetics And Millennium Report Data From Brentuximab Vedotin Phase I Clinical Trial
Oct 25, 2010: Seattle Genetics And Millennium To Highlight Brentuximab Vedotin At International Symposium On Hodgkin Lymphoma
Oct 20, 2010: Agensys And Seattle Genetics Initiate Phase I Clinical Trial Of ASG-5ME For Prostate Cancer
Oct 11, 2010: Seattle Genetics And Millennium Announce Positive Top-Line Brentuximab Vedotin Data From Phase II Trial In Systemic Anaplastic Large Cell Lymphoma
Oct 11, 2010: Seattle Genetics Reports Preliminary Data From Phase I Clinical Trial Of SGN-75
Oct 11, 2010: Seattle Genetics Reports Preliminary Data From Phase I Clinical Trial Of SGN-75
Oct 11, 2010: Seattle Genetics Reports Preliminary Data From Phase I Clinical Trial Of SGN-75
Financial Deals Landscape
Seattle Genetics, Inc., Deals Volume Summary, 2004 to YTD 2010
Seattle Genetics, Inc., Deals Summary By Region, 2004 to YTD 2010
Seattle Genetics, Inc., Deals Summary, 2004 to YTD 2010
Seattle Genetics, Inc. Detailed Deal Summary
Equity Offering
Seattle Genetics Completes Public Offering Of $136 Million
Seattle Genetics Completes Private Placement Of $11.5 Million
Seattle Genetics Completes Public Offering Of $55.8 Million
Seattle Genetics Completes Public Offering Of $103 Million
Seattle Genetics Completes Private Placement Of $5.9 Million
Seattle Genetics Completes Public Offering Of $37 Million
Seattle Genetics Enters Into Co-Development Agreement With Millennium
Seattle Genetics Expands Collaboration Agreement With Agensys
Seattle Genetics And Agensys Enter Into An Agreement
Progenics Pharmaceuticals Enters Into Agreement With Seattle Genetics
Celera Genomics Enters Into Co-Development Agreement With Seattle Genetics
Licensing Agreements
Seattle Genetics Enters Into Licensing Agreement With GlaxoSmithKline
Seattle Genetics Enters Into Licensing Agreement With Millennium Pharmaceuticals
Seattle Genetics Enters Into Licensing Agreement With Daiichi Sankyo
Seattle Genetics Amends Licensing Agreement With Bayer HealthCare
Seattle Genetics Enters Into An Agreement With MedImmune
Seattle Genetics Expands Licensing Agreement With Genentech
Genentech Enters Into Licensing Agreement With Seattle Genetics
Seattle Genetics Enters Into Licensing Agreement With PSMA Development Company
Seattle Genetics Enters Into An Agreement With MedImmune
Seattle Genetics Enters Into A Licensing Agreement With PDL BioPharma
Seattle Genetics Expands Licensing Agreement With CuraGen
Seattle Genetics Expands Licensing Agreement With Genentech
Seattle Genetics Enters Into Licensing Agreement With Bayer Pharmaceuticals
CuraGen Enters Into Licensing Agreement With Seattle Genetics
Seattle Genetics Enters Into Licensing Agreement With Imperial College London
Seattle Genetics Enters Into Licensing Agreement With Protein Design Labs
Seattle Genetics Terminates Licensing Agreement With Genentech
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Global Resource Sharing
• Sports and Fitness Nutrition - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Charter Schools - Global Outlook
• Defense Robotics - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans